Shigeru Ando

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · Journal of Medicinal Chemistry · 2022 · 590 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

Physicochemical Characterization and Structural Evaluation of a Specific 2:1 Cocrystal of Naproxen–Nicotinamide

Shigeru Ando, Junko Kikuchi, Yuko Fujimura et al. · Journal of Pharmaceutical Sciences · 2012 · 64 citations

Natural Sciences, Chemistry, Medicinal Chemistry +12

Discovery of Imidazo[1,2-<i>b</i>]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity

Ken‐ichi Kusakabe, Nobuyuki Ide, Yataro Daigo et al. · Journal of Medicinal Chemistry · 2015 · 64 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022 · 56 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +13

Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.

Shigeru Ando, Hideharu Kimura, Naomichi Iwai et al. · PubMed · 2001 · 38 citations

Medicine, Oncology, Pathology +17